Country: United States
Language: English
Source: NLM (National Library of Medicine)
LITHIUM CARBONATE (UNII: 2BMD2GNA4V) (LITHIUM CATION - UNII:8H8Z5UER66)
ANI Pharmaceuticals, Inc.
LITHIUM CARBONATE
LITHIUM CARBONATE 300 mg
ORAL
PRESCRIPTION DRUG
LITHOBID® (lithium carbonate) is indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-IV) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology. LITHOBID® is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks.
LITHOBID® (Lithium Carbonate USP) Extended-Release Tablets, 300 mg, peach-colored imprinted “LITHOBID 300” NDC 62559-280-01 Bottle of 100
New Drug Application
LITHOBID- LITHIUM CARBONATE TABLET, FILM COATED, EXTENDED RELEASE ANI PHARMACEUTICALS, INC. ---------- LITHOBID (LITHIUM CARBONATE USP) EXTENDED-RELEASE TABLETS 300 MG Rx only WARNING Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy (see DOSAGE AND ADMINISTRATION). DESCRIPTION LITHOBID tablets contain lithium carbonate, a white odorless alkaline powder with molecular formula Li CO and molecular weight 73.89. Lithium is an element of the alkali- metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. Each peach-colored, film-coated, extended-release tablet contains 300 mg of lithium carbonate. This slowly dissolving film-coated tablet is designed to give lower serum lithium peak concentrations than obtained with conventional oral lithium dosage forms. Inactive ingredients consist of calcium stearate, carnauba wax, cellulose compounds, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, povidone, propylene glycol, sodium chloride, sodium lauryl sulfate, sodium starch glycolate, sorbitol, and titanium dioxide. Product meets USP Drug Release Test 1. ACTIONS Preclinical studies have shown that lithium alters sodium transport in nerve and muscle cells and effects a shift toward intraneuronal metabolism of catecholamines, but the specific biochemical mechanism of lithium action in mania is unknown. INDICATIONS LITHOBID (lithium carbonate) is indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-IV) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology. LITHOBID is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur. Typica Read the complete document